NXL101 is a novel quinoline bacterial DNA gyrase and topoisomerase IV inhibitor that shows potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains.

NXY-059 (Cerovive) is an EGFR and HER2 autophosphorylation inhibitor, against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively.

NY0116 (NY 0116) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 27.76 uM for hNMUR1 and 13.61 uM for hNMUR2 in intracellular calcium mobilization assays.

NY-0123 is a novel potent Exchange proteins directly activated by cAMP (EPAC) antagonist with IC50 of 0.9 and 2.4 uM for EPAC1 and EPAC2, respectively.

NY0128 (NY 0128) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 29.99 uM for hNMUR1 and 10.30 uM for hNMUR2 in intracellular calcium mobilization assays.

NY-0173 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 4.0 uM for EPAC1..

O-1602 (O1602) is an atypical cannabinoid, potent and selective agonist of GPR55 cannabinoid receptor with EC50 of 13 nM, shows no significant activity for CB1 and CB2 receptors (EC50>30 uM).

OADS is a specific, reversible, small-molecule inhibitor directs against CLC (Chloride Channel) antiporter with Ki of 29 uM, has no specific effect on a CLC channel (ClC-1). .

OAT-1746 is a novel potent, selective, orally active inhibitors of Arginase 1 and 2 (ARG1/2) with IC50 of <50 nM.

OAT-177 is a potent, selective, orally active acidic mammalian chitinase (AMCase) inhibitor with IC50 of 14 and 19 nM against human and mouse AMCas, respectively, >150-fold selectivity over mCHIT1.

OAT-2068 is a potent, selective, orally bioavailable inhibitor of mouse chitotriosidase (mCHIT1) with IC50 of 29 nM, 143-fold selectivity over mAMCase.

OBA-09 is a simple ester of pyruvate and salicylic acid, main metabolites of pyruvate and aspirin, respectively, exerts robust neuroprotective effect in the postischemic brain in vivo.

Obatoclax (GX15-070) is Bcl-2 homology domain-3 (BH3) mimetic, antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L).

OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes.

Obicetrapib is a CETP inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy.

OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM.

Octahydrocurcumin is a hydrogenated derivatives of curcumin; metabolite of curcumin.

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.

Odalasvir (ACH-3102, JNJ-64289901) is a potent, second-generation HCV NS5A inhibitor in development for the treatment of hepatitis C..

ODQ (sGC inhibitor ODQ) is a potent, selective, irreversible inhibitor of sGC (soluble guanylyl cyclase).

Officinalisinin I is a steroidal saponin, isolated from Anemarrhena asphodeloides.

OGG1 inhibitor O8 is a potent, selective inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 0.22 uM, displays no significant activity against other DNA Glycosylases (NEIL1, NTH1, Fpg, IC50>50 uM)..

Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.

OGT inhibitor 4a (OSMI-4 active form) is a novel potent, selective O-linked N-acetylglucosamine transferase (OGT) inhibitor with Kd of 8 nM, the active form of OSMI-4..

OHM1 is a potent HIF1α mimic that binds to CH1 domain of p300/CBP with Kd of 500 nM, reduces the level of HIF1α transcriptional activity under hypoxia to that observed under normoxia at 20 uM in A549 cells.

Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, showsthe potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis..

Olanexidine is a monobiguanide compound with bactericidal activity.

Olcegepant hydrochloride is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and with a Ki of 14.4 pM for human CGRP.

Olcegepant(BIBN 4096; BIBN 4096BS) is the first potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor(IC50= 0.03 nM).

Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.

Oleuropein is an antioxidant polyphenol isolated from olive leaf.

Oliceridine hydrochloride (Olinvo, TRV130) is a potent, selective, and G protein biased μ opioid receptor (MOR) agonist with pEC50 of 8.1.

Olinone is a selective inhibitor for the BET BRD1 with Kd of 3.4/3.7/8.6 uM for BRD4-BrD1/BRD3-BrD1/BRD2-BrD1, respectively, shows high selectivity over BET BRD2 (Kd>300 uM).

Olumacostat glasaretil is a small molecule inhibitor of acetyl coenzyme A carboxylase (ACC).

Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for the treatment of community-acquired bacterial infections.

Omapatrilat is a dual inhibitor of the metalloproteases ACE and NEP with Ki values of 0.64 and 0.45 nM, respectively.

Ombitasvir is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).

Omidenepag Isopropyl (DE-117, OMDI) is the prodrug of Omidenepag, which is a potent, selective agonist human EP2 receptor; demonstrates excellent IOP-lowering activities following ocular administration in ocular normotensive monkeys, Omidenepag Isopropyl (OMDI) is a clinical candidate for the treatment of glaucoma.

ON 146040 is a potent, dual PI3K/BCR-ABL inhibitor with IC50 of 14/20 nM for PI3Kα/δ , IC50 of 20 nM for BCR/ABL.

ON108110 (ON-108110, ON 108110) is a novel multi-kinase inhibitor of protein kinase CK2 (CK2α1/2, IC50=3/2 nM) as well as CDK4/6 (IC50=2-24 nM).

ON1231320 is a potent selective inhibitor of Polo like kinase 2 (PLK2).

Oncrasin 1 is a proapoptotic substance. Induces abnormal nuclear aggregation of PKCι and suppressing RNA transcription.

ONO-3080573 is a potent LPA1 inhibitor with IC50 of 11 nM..

ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase.

ONO-6126 is a potent and selective PDE4 inhibitor for the treatment of bronchial asthma and allergic conjunctivitis..

ONO-9780307 is a potent LPA1 inhibitor with IC50 of 27 nM..

ONO-9910539 is a potent LPA1 inhibitor with IC50 of 22 nM..

ONO-AE3-208(AE 3-208) is an EP4 antagonist; suppresses cell invasion, migration, and metastasis of prostate cancer.

ONO-DI 004 is a potent, selective EP1 agonist..

ONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus.

Opicapone(BIA 9-1067) is a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

Opiranserin (VVZ-149, VVZ-000149) is a potent, selective, mixed glycine GlyT2 transporter blocker (IC50= 0.86 uM), purine P2X3 receptor antagonist (IC50=0.87 uM) and serotonin 5-HT2A receptor antagonist (IC50=1.3 uM).

Orally active and specific inhibitor of human hematopoietic prostaglandin D synthase (H-PGDS) (IC50 = 6 μM). Antiallergic and anti-inflammatory.

Org 26576 is a AMPA receptor positive allosteric modulator.

Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased inverse agonist affinity.

Org 42599 is a cell-permeant, allosterically binding, small-molecule agonist of luteinizing hormone (LH) receptor that rescues the folding and cell surface expression mutant mutant human LH receptors A593P and S616Y (EC50=70.8 nM)..

Org 42599 is a cell-permeant, allosterically binding, small-molecule agonist of luteinizing hormone (LH) receptor that rescues the folding and cell surface expression mutant mutant human LH receptors A593P and S616Y (EC50=70.8 nM)..

Orita-13 is potent inhibitor of Migration inhibitory factor (MIF) tautomerase activity with Ki of 17 uM..

Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria.

Oritavancin is a semisynthetic glycopeptide antibiotic that inhibits the growth of Gram-positive bacteria.

ORM-10962 is a potent, highly selective sodium-calcium exchanger (NCX) inhibitor, significantly reduces inward/outward NCX currents with IC50 of 55 and 67 nM, respectively.

ORM-15341 is a potent and full antagonist for human AR (hAR) with IC50 values of 38 nM as shown by transactivation assays in AR-HEK293 cells stably expressing full-length hAR and an androgen-responsive luciferase reporter gene construct.

Orvepitant (GW823296) is a potent and selective, brain penetrant NK1 receptor antagonist with pKi of 10.2.

Oseltamivir acid (GS 4071, Ro 64-0802, Oseltamivir carboxylate) is a potent inhibitor of influenza neuraminidase (NA) with Ki of <1 nM for both A and B strains,showed potent activity against COVID-19(SARS-COV-2).

OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively.

OSI-420 (Desmethyl Erlotinib,CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for human EGFR and EGFR autophosphorylation in tumor cells.

OSMI-1 is a cell-permeable, small molecule O-GlcNAc transferase (OGT) inhibitor with IC50 of 2.7 uM.

OSMI-4 (OGT inhibitor 4b) is a novel potent, selective, cell-active O-linked N-acetylglucosamine transferase (OGT) inhibitor with EC50 of ~3 uM.

OSU-03012(AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067.

OSW-1 is a natural anti-enterovirus and anti-cancer compound that targets oxysterol-binding protein (OSBP) with Ki of 26 and 54 nM for OSBP and ORP4L, respectively.

Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.

Otilonium Bromide is an antimuscarinic used as a spasmolytic agent.

OTS186935 (OTS-186935) is a potent, in vivo-active inhibitor of protein methyltransferase SUV39H2 with IC50 of 6.49 nM, inhibits A549 cell growth with IC50 of 0.67 uM; causes a significant growth inhibitory effect in mouse xenograft models using MDA-MB-231 breast cancer cells as well as A549 lung cancer cells, at 25 mg/kg once daily for 14 days yielded a TGI of 60.8%; attenuates the levels of H3K9me3 in A549 xenograft mouse model.

OTS193320 (OTS-193320) is a potent inhibitor of protein methyltransferase SUV39H2 with IC50 of 22.2 nM.

OUL35 (NSC39047) is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of 330 nM, displays remarkable selectivity towards ARTD10 over other enzymes in the human protein family.

OUL35 derivative 32 is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of230 nM, rescues HeLa cells from ARTD10-induced cell death..

OUP-16 is a potent H4R agonist with a considerable selectivity over H3R..

o-vanillin (C29L.

OX-14 is a highly potent farnesyl pyrophosphate synthase (FPPS) inhibitor with IC50 of 2.46 nM, with significantly lower binding affinity to hydroxyapatite.

Oxadiazon is a preemergent herbicide.

Oxaliplatin is a second generation potent platinum-based anti-neoplastic agent that is believed to form inter- and intrastrand DNA adducts which activate signaling pathways culminating in apoptosis. The development of Oxaliplatin was inspired from the eff

Oxybenzone is a benzophenone derivative used as a sunscreen agent.

Oxythiamine chloride is a small molecule transketolase inhibitor with Kd of 33 nM, shows functional assay of human transketolase inhibition in HCT-116 cells with EC50 of 26 nM.

Oxythiamine, an antimetabolite and a vitamin B1 antagonist, is a well-known thiamine antagonist and inhibitor of transketolase.

Ozagrel(OKY-046) sodium salt is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.

P053 (P-053, CerS1 inhibitor P053) is a potent, selective, orally active inhibitor of ceramide synthase 1 (CerS1) with IC50 of 0.5 uM, displays >10-fold selectivity for inhibition of CerS2, CerS4, CerS5, and CerS6.

p32 inhibitor M36 is a novel small molecule inhibitor of p32 mitochondrial protein, binds directly to p32 and inhibits p32 association with LyP-1.

p38 MAPK-IN-4 is a potent and selective inhibitor of p38 MAPK with IC50 of 68 nM for p38α, inhibits LPS-induced TNFα release in THP-1 cells with IC50 of 187 nM.

p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1.

P516-0475 is a novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO (IC50=10 uM).

P53R3 is a novel p53 reactivator that restores sequence-specific DNA binding of the endogenously expressed p53(R175H) and p53(R273H) mutants in gel-shift assays.

P62-mediated mitophagy inducer (PMI) is a small molecule P62-mediated mitophagy inducer that activates mitophagy without recruiting Parkin or collapsing membrane potential and retains activity in cells devoid of a fully functional PINK1/Parkin pathway.

PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation..

PAC-14028 is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist.

PACAP (6-38), human, ovine, rat is a potent PACAP receptor antagonist with IC50s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively.

Pacritinib (SB1518) is a potent and selective JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, respectively) and FLT3 (IC(50) = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50= 1280 and 520 nM, respectively).

Pactamycin (NSC 52947) is a potent protein synthesis inhibitor, inhibits protein synthesis at the translocation step on the 70S ribosome, has activity against Gram-positive and Gram-negative bacteria, and broad antitumor, antiviral, and antiplasmodial act

Padsevonil (UCB-0942, UCB0942) is a potential anti-seizure agent that functions as a pre- and post-synaptic inhibitor..

PAFAH inhibitor P11 (P11) is a potent, selective platelet-activating factor acetylhydrolases PAFAH1b2 and PAFAH1b3 inhibitor with IC50 of 40 nM and 900 nM respectively.

Pagoclone is an active (+)-enantiomer of the racemate RP 59037. Pagoclone is a partial GABA(A) receptor agonist used for the treatment of panic and anxiety disorders.

Palmitelaidic acid is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.

Palmitoylethanolamide(PEA) is an endogenous fatty acid amide and selectively activates PPAR-α in vitro with an EC50 value of 3.1±0.4 μM.

Palmostatin B is a potent Acyl protein thioesterase 1 (APT1.

Pamiparib (BGB-290, BGB290) is a highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.

Panadiplon (U-78875) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type.

Pandacostat is the first nonselective HDAC inhibitor (pan-HDACi) with Ki of 0.12/0.07/0.95/0.18/0.032/1.1/0.5/1.4 uM for HDAC1/2/3/4/5/6/7/8/9, respectively.

pan-PIM inhibitor 17 is a potent, selective, orally available inhibitor of Pim kinase with IC50 of 0.8, 5.1 and 1.8 nM for Pim1, 2 and 3, respectively.

Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors.

Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Papain is a cysteine protease of the peptidase C1 family, which is used in food, pharmaceutical, textile, and cosmetic industries.

PAPTP is a PAP-1 derivative, potent, specific Kv1.3 channel inhibitor with IC50 of 31 nM in Jurkat T lymphocytes by patch-clamp, reduces cell viability and efficiently kills B16F10 cancer cells at 1 uM.

PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells.

Paradol(6-Paradol) is the active flavor constituent of the seeds of Guinea pepper (Aframomum melegueta); Paradol has been found to have antioxidative and antitumor promoting effects.

Parecoxib is a selective COX2 inhibitor.

Paricalcitol

Paroxetine hydrochloride hemihydrate is a antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs).

PARP10 inhibitor 22 is a selective, cell-active inhibitor of PARP10 with IC50 of 1.8 uM, exhibits >10-fold selectivity over a large subset of other PARP family members.

PARP11 inhibitor ITK7 (ITK7) is a potent and selective PARP11 inhibitor with IC50 of 14 nM, displays >200-fold selectivity over other PARPs.

PARP14 inhibitor H10 (H10) is a potent, selective, cell-active PARP14 inhibitor with IC50 of 490 nM, with good selectivity over other PARPs (24-fold and 18-fold over PARP1 and TNKS1, respectively).

PAT-048 (PAT048) is a potent, selective, noncompetitive autotaxin inhibitor with IC50 of 1.1 nM against the lysoPLD activity of human ATX.

PAT-1251 (PAT 1251, PAT1251) is a potent, selective and orally bioavailable lysyl oxidase-like 2 (LOXL2) inhibitor with IC50 of 0.71 uM in human whole blood assays, with high selectivity over LOX (400-fold) and other amine oxidases.

PAT-505 (PAT 505, PAT505) is a potent, selective, noncompetitive, and orally active autotaxin inhibitor with IC50 of 2.0 nM against the lysoPLD activity of human ATX.

Paullinic acid is a long-chain fatty acid that has been detected in multiple biofluids, such as blood and urine.

Pax2 inhibitor EG1 (EG1) is a potent, small molecule inhibitor of Pax2 mediated transcription activation, effectively blocks Pax2 activity and DNA binding with Kd of 1.35-1.5 uM; inhibits Pax2 mediated expression with IC50 of 10 uM, and inhibits proliferation of Pax2 positive renal and ovarian cancer cell lines but has little effect on Pax2 negative cancer cells; inhibits embryonic kidney development.

PAβN dihydrochloride (MC-207110 dihydrochloride) is an efflux pump inhibitor.

PBF509 (PBF-509, NIR 178) is a novel selective and potent Adenosine A2A Receptor (A2AR) antagonist, antagonizes A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 and 8.2 nM, respectively.

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.

PBT434 is a novel quinazolinone compound with effect of lowering cellular iron levels, prevents iron mediated neurodegeneration and α-synuclein toxicity in multiple models of Parkinson disease; inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein, a protein that aggregates in the neuropathology; prevents loss of substantia nigra pars compacta neurons (SNpc), lowers nigral α-synuclein accumulation, and rescues motor performance in mice model of PD.

PC1244 is a long acting fungicidal azole that targets A. fumigatus CYP51A and CYP51B, inhibits ergosterol synthesis in A. fumigatus with IC50 of 8 nM.

PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively.

PCAF BRD inhibitor L-45 is a potent, selective, and cell-active PCAF bromodomain inhibitor with Ki of 47 nM in HTRF assays, >4,500-fold selectivity over BRD4.

PCARBTP is a derivative, potent, specific Kv1.3 channel inhibitor, reduces cell viability and efficiently kills B16F10 cancer cells at 1 uM.

PCC0104005 (PCC-0104005) is a novel modulator of serotonin, dopamine, and noradrenaline receptors, including partial agonism at dopamine D2, D3, D4, serotonin 5-HT1A, and 5-HT2A receptors and antagonism at 5-HT2B, 5-HT6, and 5-HT7 receptors.

PCI-33380 is an irreversible Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe).

PCO371 is a novel, orally active small molecule that acts as a full agonist of PTHR1.

PCSK9 modulator 10 is a highly potent, orally active PCSK9 modulator that inhibits PCSK9 production in HepG2 cells with IC50 of 0.036 nM.

PCSK9-IN-7l is a potent, small molecule PCSK9 mRNA translation inhibitor with IC50 of 1.37 uM, shows limited bone marrow toxicity (IC50=27.1 uM)..

PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

PD166285 (PD 0166285) is a broad-spectrum receptor tyrosine kinase (RTK) inhibitor that inhibits PDGFR-β, EGFR, and FGFR1 and c-Src with IC50 of 7-85 nM.

PD-168077 maleate is a selective dopamine D4 receptor agonist, with a Ki of 9 nM.

PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth.

PD1-IN-2 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.

PD1-PD L1 inhibitor Polaris is a novel potent, small molecule inhibitor of PD-1/PD-L1 interaction (IC50=0.1-10 nM in ELISA assays) with anti-cancer activity.

PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.

PDD 00017273 is the first-in-class, selective inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with Kd, biochemical EC50 of 1.45 nM, 26 nM.

PDE10A-IN-31 is a potent, highly selective PDE10A inhibitor with IC50 of 2 nM for both rPDE10A and hPDE10A.

PDE10A-IN-32 is a potent, highly selective, brain penetrant PDE10A inhibitor with IC50 of 0.14 nM, displays no significant activity against other PDEs (IC50>1,000 nM)..

PDE1-IN-2 is an inhibitor of PDE1 extracted from patent WO2016/55618 A1, example 31; has IC50 values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectvely.

PDE2 inhibitor 4 is a potent, selective, orally available inhibitor of PDE2 with IC50 of 2 nM, displays high selectivity versus other PDE isoforms.

PDE4D-IN-26b is a potent, highly selective PDE4D inhibitor with IC50 of 0.6 nM, displays 75-fold lower activity against the PDE4A, B, and C subtypes, also exhibits 18,000-fold decreased potency against other PDE family members.

PDEδ-IN-99 is a novel potent K-Ras-PDEδ inhibitor that binds to the farnesyl binding pocket of PDEδ with Kd of 8±4 nM..

PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively.

PDK1 inhibitor is a potent and selective inhibitor of PDK1 with potential as anticancer agent..

Pemafibrate is an orally bioavailable and selective agonist of peroxisome proliferator-activated receptor α (PPARα; EC50 = 1 nM for transcriptional activity), a transcription factor that is essential for regulation of lipid homeostasis.

Pemigatinib is a selective FGFR inhibitor in development for the treatment of patients with cholangiocarcinoma.

Pentanoic acid, a short-chain fatty acid, is a product of bacterial metabolism and are associated with allergic skin disorders. Pentanoic acid activates ROCK signaling pathway.

PEO-IAA is an indole-3-acetic acid (IAA) antagonist. PEO-IAA is an auxin antagonist that binds to transport inhibitor response 1/auxin signaling F-box proteins (TIR1/AFBs).

Pepstatin Ammonium is a specific aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and he

Peptide Fz7-21 is a potent, selective peptide inhibitor of Frizzled 7 receptor, inhibits exogenous WNT3A stimulated Wnt-β-catenin signaling in HEK293 cells with IC50 of 100 nM.

Peptide P60 (FOXP3 inhibitor P60) is a 15-mer synthetic peptide, cell-permeable inhibitor of FOXP3, binds specifically to FOXP3; inhibits murine and human-derived Treg and improves effector T cell stimulation, overcomes the inhibitory effect of FOXP3 on the activity of the transcription factors NF-κB and NFAT, inhibits upregulation of mRNA for Foxp3 and IL-10 on effector T cells and enhances mRNA for IFN-γ after anti-CD3 stimulation; induces a scurfy-like disease in newborn mice, improves vaccine efficacy in mice model of CT26 tumor and HCV infection.

Perhexiline is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2).

Perhexiline maleate (WSM 3978G) is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2).

Perisesaccharide B is an oligosaccharide isolated from the root barks of Periploca sepium.

Perisesaccharide C is an oligosaccharide isolated from the root barks of Periploca sepium.

Perlapine (AW-14233.

Pertussis Toxin is a protein-based AB5-type exotoxin produced by the bacterium Bordetella pertussis, which causes whooping cough.

Petroselinic acid, a positional isomer of oleic acid, is isolated from the vegetable oil of Coriandrum sativum fruits.

PF 03709270 is an orally available ester prodrug form of sulopenem, with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria.

PF 03716556 is a potent, and selective acid pump (H+,K+ ATPase) antagonist, with pIC50 value of 6.009.

PF 04878691 (PF 4878691, S 32865, 852A, 3M 001) is a selective TLR7 agonist that potently induces IFN-α and IFN-regulated proteins from human PBMC.

PF 477736 is a CHK inhitor with Ki values of 0.49 and 47 nM for Chk1 and Chk2 respectively. A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity

PF 4800567 is a selective casein kinase 1ε inhibitor; displays 22-fold greater potency towards CK1ε than CK1δ (IC50 values are 32 and 711 nM for CK1ε and CK1δ respectively).

PF 5212372 (PLA-950, ZPL-521, ZPL 5212372) is a potent, selective inhibitor of cPLA2 (cytosolic phospholipase A2α) with IC50 of 7 nM.

PF 6260933 is a potent, selective and orally bioavailable MAP4K4 inhibitor with kinase IC50 of 3.7 nM, cell IC50 of 160 nM.

PF 750 is a selective and covalent fatty acid amide hydrolase (FAAH) inhibitor, with IC50s varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme’s active site serine nucleophile.

PF-00446687 hydrochloride (PF-446687) is a potent, selective melanocortin-4 receptor (MC4R) agonist with EC50 of 12 nM.

PF-00446687(PF-446687) is a potent, selective melanocortin-4 receptor (MC4R) agonist with EC50 of 12 nM.

PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively.

PF-00610355 (PF 610355) is a potent, selective, and long-acting β2-adrenoreceptor agonist with EC50 of 0.26 nM.

PF-02413873 (PF-2413873) is a potent, selective, fully competitive, and orally active progesterone receptor (PR) antagonist with Ki of 9.7 nM.

PF-02575799 is a highly potent microsomal triglyceride transfer protein (MTP) inhibitor with IC50 of 0.77 nM.

PF-03049423 is a potent, selective, orally active, and brain penetrant inhibitor of PDE5 with IC50 of 0.2 nM.

PF-03382792 (PF-3382792) is a clinical compound under phase 1 investigation for an unknown indication..

PF-03463275 (PF 3463275) ia an orally bioavailable, centrally penetrant, potent, reversible, selective, and competitive inhibitor of the human GlyT1 transporter with Ki of 13 nM.

PF-03654746 (PF 3654746) is a potent, selective, orally bioactive antagonist of H3 receptor with Ki of 2.3 nM.

PF-03654764 (PF 3654764) is a potent, selective, orally bioactive antagonist of H3 receptor with Ki of 1.4 nM.

PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2].PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP’s 2C9 and CYP3A4[2].PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively[2]. Animal Model: Male CD Sprague Dawley rats (300-450 g)[2] Dosage: 1 mg/kg Administration: I.v. (Pharmacokinetic Analysis) Result: The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively.

PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity.

PF-03814735 is a novel, potent, orally bioavailable, reversible small-molecule Aurora kinase inhibitor with IC50 of 0.8, 5, 10 and 22 nM for Aurora A, Aurora B, Flt 1 and FAk, respectively.

PF-03882845 is highly potent, selective, nonsteroidal, orally bioavailable Mineralocorticoid receptor antagonist with IC50 of 4.5 nM.

PF-04191834 (PF-4191834) is a potent, non‐iron chelating, non‐redox, selective and competitive inhibitor of 5-lipoxygenase (5‐LO) with Ki of 10 nM.

PF-04217903 is a potent, selective, ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM, inhibits HGF-stimulated tyrosine phosphorylation of wild type c-Met with IC50 of 7.3 nM in cell-based assays.

PF-04308515 (PF 4308515) is a potent glucocorticoid receptor (GR) agonist with anti-inflammatory activity..

PF-04449613 (PF04449613) is a potent and selective inhibitor of PDE9..

PF-04449913 is a potent and orally bioavailable inhibitor of smoothened with IC50 of 5 nM(Gli-luciferase reporter reporter in C3H10T1/2); the hedgehog pathway inhibitor

PF-04455242 is a potent, selective κ-opioid receptor (KOR) antagonist with Ki of 3 nM/21 nM/22 nM for hKOR/rKOR/mKOR, respectively.

PF-04455242 is a potent, selective κ-opioid receptor (KOR) antagonist with Ki of 3 nM/21 nM/22 nM for hKOR/rKOR/mKOR, respectively.

PF-04531083 (PF 4531083) is a potent and selective, orally available sodium channel Nav1.8 blocker for treatment of pain. .

PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM.